Palvella Therapeutics (PI6) Price & Analysis

0 Followers

PI6 Stock Chart & Stats

€104.00

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€104.00

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€31.40 - €136.00

Previous CloseN/A

Volume0.00

Average Volume (3M)1.00

Market Cap

€1.81B

Enterprise Value€1.39K

Total Cash (Recent Filing)€261.85M

Total Debt (Recent Filing)€584.00K

Price to Earnings (P/E)―

Beta0.42

Next Earnings

Aug 13, 2026

EPS Estimate

-1.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.17

Shares Outstanding14,342,844

10 Day Avg. Volume1

30 Day Avg. Volume1

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)42.09

Price to Sales (P/S)0.00

P/FCF Ratio-47.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€205.87

Price Target Upside97.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-4.86

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical & Regulatory MomentumPositive Phase 3 SELVA results plus multiple expedited regulatory designations and a rolling FDA review materially de-risk Palvella's lead program over the coming months. This advances a clear NDA pathway and, if sustained, creates a durable route to first-in-disease approval and market entry.

Strong Balance Sheet & FundingA sizable, recently upsized financing provides multi-quarter runway to complete NDA filing, invest in commercialization readiness, and support additional trials. Combined with very low reported debt, this capital base meaningfully reduces near-term liquidity risk and supports execution toward regulatory milestones.

Strengthened Governance & Commercial BenchAdding an experienced rare-disease commercial executive to the board and expanding equity incentives strengthens oversight and launch capability. This improves long-term execution odds for market access, sales force build-out, and reimbursement strategy—key durable drivers for a pre-commercial biotech.

Bears Say

No Product RevenueAs a clinical-stage company with no commercialized products, Palvella has zero product revenue and mounting net losses. Sustainable profitability depends on successful regulatory approval and commercial uptake, so near-term fundamentals remain tied to binary development outcomes rather than recurring cash flow.

Accelerating Cash BurnOperating cash flow and free cash flow are increasingly negative, reflecting higher R&D and G&A as the company prepares for NDA and launch. Even with current cash reserves, accelerating burn means Palvella remains dependent on capital markets or milestones to replenish resources before sustained commercial revenues.

Pre-commercial Execution RiskTransitioning from clinical success to revenue requires building a salesforce, securing reimbursement, and achieving adoption in rare-disease clinics. These operational and market-access tasks carry execution and timing risk that could delay revenue realization beyond current timelines and pressure cash runway.

Palvella Therapeutics News

H.C. Wainwright says Palvella selloff ‘an overreaction’ to FDA’s BTD denial

H.C. Wainwright notes that on Monday, Palvella Therapeutics (PVLA) closed down 21% compared to the previous weeks close,...

2d ago

PVLA

Palvella Therapeutics selloff a buying opportunity, says BTIG

Palvella shares fell sharply after the FDA declined to grant Breakthrough Therapy Designation for QTORIN in cVMs, but...

3d ago

PVLA

Palvella Therapeutics falls -13.6%

Palvella Therapeutics (PVLA) is down -13.6%, or -$21.36 to $135.88. Published first on TheFly – the ultimate source...

3d ago

PVLA

Palvella Therapeutics falls -9.0%

Palvella Therapeutics (PVLA) is down -9.0%, or -$14.11 to $143.13. Published first on TheFly – the ultimate source...

3d ago

PVLA

Ligand price target raised to $345 from $330 at Craig-Hallum

Craig-Hallum analyst Matt Hewitt raised the firm’s price target on Ligand (LGND) to $345 from $330 and keeps...

3d ago

SNY

LGND

Palvella Therapeutics appoints Savara CEO Matt Pauls to board

Palvella Therapeutics (PVLA) announced the appointment of Matt Pauls to its board of directors. Since 2020, he has...

24d ago

PVLA

SVRA

Palvella submits first rolling new drug application to FDA for Qtorin

Palvella Therapeutics (PVLA) announced that the company has submitted the first module of its rolling new drug application,...

25d ago

PVLA

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

WSW, NY, July 22nd, 2026, FinanceWire Ten billion dollars. That is what Vertex Pharmaceuticals (Nasdaq:VRTX) agreed to pay...

1d ago

PTN

CRNX

Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target

Whitney Ijem, an analyst from Canaccord Genuity, reiterated the Buy rating on Palvella Therapeutics. The associated price target...

2d ago

PVLA

Palvella Pharmaceuticals: Buy Rating Reiterated as QTORIN Regulatory Path Stays Intact; Price Target Unchanged at $225

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Palvella Therapeutics yesterday and set a price target...

2d ago

PVLA

Palvella Therapeutics Highlights Growth Plans and QTORIN Progress

Palvella Therapeutics ( ($PVLA) ) has issued an announcement. On July 14, 2026, Palvella Therapeutics posted a new...

9d ago

PVLA

Palvella Therapeutics Adds Industry Veteran to Board

The latest announcement is out from Palvella Therapeutics ( ($PVLA) ). On June 29, 2026, Palvella Therapeutics, Inc....

24d ago

PVLA

FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin

Palvella Therapeutics (PVLA) announced today that FDA has granted rolling review for the company’s new drug application, or...

1M ago

PVLA

Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership

Palvella Therapeutics ( ($PVLA) ) has provided an announcement. On June 10, 2026, at its Annual Meeting of...

1M ago

PVLA

PI6 FAQ

What was Palvella Therapeutics, Inc.’s price range in the past 12 months?

Palvella Therapeutics, Inc. lowest stock price was €31.40 and its highest was €136.00 in the past 12 months.

What is Palvella Therapeutics, Inc.’s market cap?

Palvella Therapeutics, Inc.’s market cap is €1.81B.

When is Palvella Therapeutics, Inc.’s upcoming earnings report date?

Palvella Therapeutics, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 20 days.

How were Palvella Therapeutics, Inc.’s earnings last quarter?

Palvella Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -€1.051 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Palvella Therapeutics, Inc. overvalued?

According to Wall Street analysts Palvella Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palvella Therapeutics, Inc. pay dividends?

Palvella Therapeutics, Inc. does not currently pay dividends.

What is Palvella Therapeutics, Inc.’s EPS estimate?

Palvella Therapeutics, Inc.’s EPS estimate is -1.03.

How many shares outstanding does Palvella Therapeutics, Inc. have?

Palvella Therapeutics, Inc. has 14,342,844 shares outstanding.

What happened to Palvella Therapeutics, Inc.’s price movement after its last earnings report?

Palvella Therapeutics, Inc. reported an EPS of -€1.051 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Palvella Therapeutics, Inc.?

Currently, no hedge funds are holding shares in DE:PI6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Palvella Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

232.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Palvella Therapeutics (PI6) Earnings & Revenues

Historic Earnings Reports

PI6 Stock 12 Month Forecast

Average Price Target

€205.87

▲(97.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","237":"€237","71.25":"€71.3","126.5":"€126.5","181.75":"€181.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":236.1258567,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€236.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":205.86676543400003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€205.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":179.28074305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€179.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,71.25,126.5,181.75,237],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133,140.9327582076923,148.8655164153846,156.79827462307694,164.73103283076924,172.66379103846154,180.59654924615384,188.52930745384617,196.46206566153847,204.39482386923078,212.32758207692308,220.26034028461538,228.19309849230768,{"y":236.1258567,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133,138.6051358026154,144.2102716052308,149.81540740784615,155.42054321046155,161.02567901307694,166.63081481569233,172.2359506183077,177.8410864209231,183.44622222353848,189.05135802615388,194.65649382876927,200.26162963138466,{"y":205.86676543400003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133,136.5600571576923,140.12011431538463,143.68017147307694,147.24022863076922,150.80028578846154,154.36034294615385,157.92040010384616,161.48045726153848,165.04051441923076,168.60057157692307,172.1606287346154,175.7206858923077,{"y":179.28074305,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >